Loading...
•
Dec 31, 2022
Janux Q4 2022 Earnings Report
Janux transitioned to a clinical-stage company by dosing the first patient with PSMA-TRACTr and advancing its pipeline utilizing its novel TRACTr and TRACIr platforms.
Key Takeaways
Janux Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022. The company's lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients and Janux received FDA clearance for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008).
Lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients.
Janux received U.S. Food and Drug Administration (FDA) clearance for an IND application for EGFR-TRACTr (JANX008).
PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.
TROP2-TRACTr evaluations to support development candidate selection are ongoing.
Forward Guidance
Janux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...